Galileo – Biotech Innovation Fund BC USD

Reference Data

ISIN LU2226244361
Valor Number
Bloomberg Global ID
Fund Name Galileo – Biotech Innovation Fund BC USD
Fund Provider IPConcept (Luxemburg) S.A. Zürich, Switzerland
Phone: +352 260248-1
E-Mail: info.lu@ipconcept.com
Web: www.ipconcept.com
Fund Provider IPConcept (Luxemburg) S.A.
Representative in Switzerland IPConcept (Schweiz) AG
Zürich
Phone: +41 044 224 32 09
Distributor(s) Bellecapital AG
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark.
Peculiarities

Fund Prices

Current Price * 56.95 USD 22.12.2025
Previous Price * 56.13 USD 19.12.2025
52 Week High * 61.74 USD 16.10.2025
52 Week Low * 33.21 USD 09.04.2025
NAV * 56.95 USD 22.12.2025
Issue Price * 56.95 USD 22.12.2025
Redemption Price * 56.95 USD 22.12.2025
Closing Price *
Indicative Minimum Price
Fund Assets *** 41,063,442
Unit/Share Assets *** 39,959,602
Trading Information SIX

Performance

YTD Performance +21.25% 30.12.2024
22.12.2025
YTD Performance (in CHF) +6.61% 30.12.2024
22.12.2025
1 month +3.87% 24.11.2025
22.12.2025
3 months +19.14% 22.09.2025
22.12.2025
6 months +43.70% 24.06.2025
22.12.2025
1 year +20.94% 23.12.2024
22.12.2025
2 years +2.37% 22.12.2023
22.12.2025
3 years -14.41% 22.12.2022
22.12.2025
5 years -62.03% 31.03.2021
22.12.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Arcellx Inc 9.14%
Alnylam Pharmaceuticals Inc 7.04%
Krystal Biotech Inc 6.92%
Vertex Pharmaceuticals Inc 5.64%
BioNTech SE ADR 4.97%
Regeneron Pharmaceuticals Inc 4.37%
Stoke Therapeutics Inc 4.04%
Gilead Sciences Inc 3.56%
CARsgen Therapeutics Holdings Ltd Ordinary Shares 3.30%
uniQure NV 3.07%
Last data update 31.05.2025

Cost / Risk

TER
TER date
Performance Fee ***
PTR
Max. Management Fee ***
Ongoing Charges *** 0.47%
SRRI ***
SRRI date *** 30.11.2025

Breakdowns

Equity Countries ***

Equity Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)